MA38724B1 - Formulation liquide stable d'amg 416 (velcalcétide) - Google Patents
Formulation liquide stable d'amg 416 (velcalcétide)Info
- Publication number
- MA38724B1 MA38724B1 MA38724A MA38724A MA38724B1 MA 38724 B1 MA38724 B1 MA 38724B1 MA 38724 A MA38724 A MA 38724A MA 38724 A MA38724 A MA 38724A MA 38724 B1 MA38724 B1 MA 38724B1
- Authority
- MA
- Morocco
- Prior art keywords
- velcalctide
- amg
- liquid formulation
- stable liquid
- formulation
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract 2
- ANIAZGVDEUQPRI-ZJQCGQFWSA-N etelcalcetide Chemical compound NC(N)=NCCC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O ANIAZGVDEUQPRI-ZJQCGQFWSA-N 0.000 title 1
- 229950006502 etelcalcetide Drugs 0.000 title 1
- 108091022127 etelcalcetide hydrochloride Proteins 0.000 title 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04D—NON-POSITIVE-DISPLACEMENT PUMPS
- F04D25/00—Pumping installations or systems
- F04D25/02—Units comprising pumps and their driving means
- F04D25/06—Units comprising pumps and their driving means the pump being electrically driven
- F04D25/0606—Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
- F01D15/00—Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
- F01D15/10—Adaptations for driving, or combinations with, electric generators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Mechanical Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne une formulation liquide comprenant un agoniste peptidique du récepteur sensible au calcium, et un procédé de préparation et d'utilisation de cette formulation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361840618P | 2013-06-28 | 2013-06-28 | |
| PCT/US2014/044622 WO2014210489A1 (fr) | 2013-06-28 | 2014-06-27 | Formulation liquide stable d'amg 416 (velcalcétide) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38724A1 MA38724A1 (fr) | 2017-03-31 |
| MA38724B1 true MA38724B1 (fr) | 2017-11-30 |
Family
ID=51213030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38724A MA38724B1 (fr) | 2013-06-28 | 2014-06-27 | Formulation liquide stable d'amg 416 (velcalcétide) |
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US9820938B2 (fr) |
| EP (3) | EP3878433A1 (fr) |
| JP (1) | JP6027708B2 (fr) |
| KR (1) | KR102231957B1 (fr) |
| CN (2) | CN105764487A (fr) |
| AP (1) | AP2015008936A0 (fr) |
| AR (1) | AR096773A1 (fr) |
| AU (1) | AU2014302122B2 (fr) |
| CA (1) | CA2916222C (fr) |
| CL (1) | CL2015003738A1 (fr) |
| CR (2) | CR20160061A (fr) |
| CY (1) | CY1120811T1 (fr) |
| DK (1) | DK3013318T3 (fr) |
| EA (1) | EA030220B1 (fr) |
| ES (1) | ES2633989T3 (fr) |
| HR (1) | HRP20171092T1 (fr) |
| HU (1) | HUE034209T2 (fr) |
| IL (1) | IL243210B (fr) |
| JO (1) | JO3817B1 (fr) |
| LT (1) | LT3013318T (fr) |
| MA (1) | MA38724B1 (fr) |
| ME (1) | ME02818B (fr) |
| MX (1) | MX2015017952A (fr) |
| MY (1) | MY180276A (fr) |
| PE (2) | PE20160549A1 (fr) |
| PH (1) | PH12015502816B1 (fr) |
| PL (1) | PL3013318T3 (fr) |
| PT (1) | PT3013318T (fr) |
| RS (1) | RS56238B1 (fr) |
| SG (1) | SG11201510647TA (fr) |
| SI (1) | SI3013318T1 (fr) |
| SM (1) | SMT201700401T1 (fr) |
| TN (1) | TN2015000569A1 (fr) |
| TW (1) | TWI635874B (fr) |
| UA (1) | UA115373C2 (fr) |
| UY (1) | UY35636A (fr) |
| WO (1) | WO2014210489A1 (fr) |
| ZA (1) | ZA201600238B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201700401T1 (it) | 2013-06-28 | 2017-09-07 | Amgen Inc | Formulazione liquida stabile di amg 416 (velcalcetide) |
| JP6710158B2 (ja) | 2014-04-03 | 2020-06-17 | アムジェン インコーポレイテッド | Ａｍｇ４１６の製造方法 |
| US10858389B2 (en) | 2015-03-26 | 2020-12-08 | Amgen Inc. | Solution phase method for preparing etelcalcetide |
| CN106137979A (zh) * | 2015-03-31 | 2016-11-23 | 深圳翰宇药业股份有限公司 | 一种冻干粉针剂及其制备方法 |
| CN106928320B (zh) | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| CN106928321B (zh) * | 2015-12-31 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| CN110054662B (zh) * | 2018-01-18 | 2021-03-02 | 成都圣诺生物制药有限公司 | 一种固相合成Etelcalcetide的方法 |
| WO2021231960A1 (fr) | 2020-05-15 | 2021-11-18 | Amgen Inc. | Méthodes de traitement de l'hypertrophie ventriculaire gauche |
| CN111925415A (zh) * | 2020-08-10 | 2020-11-13 | 海南中和药业股份有限公司 | 一种维拉卡肽杂质的制备方法 |
| WO2022034545A1 (fr) * | 2020-08-14 | 2022-02-17 | Aurobindo Pharma Limited | Formulations d'ételcalcetide à usage parentéral |
| MX2023013066A (es) | 2021-05-06 | 2023-11-15 | Amgen Inc | Formulaciones de etelcalcetida. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69703121D1 (de) | 1996-10-25 | 2000-10-19 | Us Health | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit |
| AT409081B (de) | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| ATE541582T1 (de) * | 2003-06-03 | 2012-02-15 | Novo Nordisk As | Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen |
| CA2527743A1 (fr) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Compositions pharmaceutiques peptidiques stabilisees |
| US7265092B2 (en) | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| JP5645408B2 (ja) * | 2006-11-16 | 2014-12-24 | カイ ファーマシューティカルズ インコーポレーティッド | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
| KR20090115852A (ko) | 2007-01-19 | 2009-11-09 | 카이 파마슈티컬즈 | 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 |
| ES2412707T5 (es) | 2009-06-19 | 2023-06-12 | Procter & Gamble | Composición detergente líquida para lavado de vajillas a mano |
| ES2729051T3 (es) * | 2009-07-29 | 2019-10-30 | Kai Pharmaceuticals Inc | Agentes terapéuticos para reducir los niveles de hormona paratiroidea |
| EP2399604A1 (fr) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Nouvelle formulation d'anticorps |
| WO2012075375A1 (fr) * | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Administration d'hormones parathyroïdiennes par des systèmes de micro-injection |
| CN103857405B (zh) * | 2011-06-08 | 2015-12-02 | 凯伊药品公司 | 用于调节血清磷的治疗剂 |
| CN104168955A (zh) | 2011-11-10 | 2014-11-26 | 凯伊药品公司 | 拟钙剂及其使用方法 |
| SMT201700401T1 (it) | 2013-06-28 | 2017-09-07 | Amgen Inc | Formulazione liquida stabile di amg 416 (velcalcetide) |
| JP6710158B2 (ja) * | 2014-04-03 | 2020-06-17 | アムジェン インコーポレイテッド | Ａｍｇ４１６の製造方法 |
-
2014
- 2014-06-27 SM SM20170401T patent/SMT201700401T1/it unknown
- 2014-06-27 EA EA201690099A patent/EA030220B1/ru not_active IP Right Cessation
- 2014-06-27 MX MX2015017952A patent/MX2015017952A/es active IP Right Grant
- 2014-06-27 DK DK14742093.9T patent/DK3013318T3/en active
- 2014-06-27 EP EP21156687.2A patent/EP3878433A1/fr active Pending
- 2014-06-27 CN CN201480047399.7A patent/CN105764487A/zh active Pending
- 2014-06-27 JP JP2016524250A patent/JP6027708B2/ja active Active
- 2014-06-27 PL PL14742093T patent/PL3013318T3/pl unknown
- 2014-06-27 CN CN202111597304.7A patent/CN114376970A/zh active Pending
- 2014-06-27 PE PE2015002666A patent/PE20160549A1/es unknown
- 2014-06-27 UA UAA201600641A patent/UA115373C2/uk unknown
- 2014-06-27 PT PT147420939T patent/PT3013318T/pt unknown
- 2014-06-27 AU AU2014302122A patent/AU2014302122B2/en active Active
- 2014-06-27 LT LTEP14742093.9T patent/LT3013318T/lt unknown
- 2014-06-27 WO PCT/US2014/044622 patent/WO2014210489A1/fr not_active Ceased
- 2014-06-27 RS RS20170704A patent/RS56238B1/sr unknown
- 2014-06-27 HU HUE14742093A patent/HUE034209T2/en unknown
- 2014-06-27 KR KR1020167002370A patent/KR102231957B1/ko active Active
- 2014-06-27 AP AP2015008936A patent/AP2015008936A0/xx unknown
- 2014-06-27 US US14/908,481 patent/US9820938B2/en active Active
- 2014-06-27 EP EP14742093.9A patent/EP3013318B1/fr active Active
- 2014-06-27 CR CR20160061A patent/CR20160061A/es unknown
- 2014-06-27 HR HRP20171092TT patent/HRP20171092T1/hr unknown
- 2014-06-27 PE PE2020001772A patent/PE20210413A1/es unknown
- 2014-06-27 MY MYPI2015003044A patent/MY180276A/en unknown
- 2014-06-27 CR CR20160002A patent/CR20160002A/es unknown
- 2014-06-27 TW TW103122433A patent/TWI635874B/zh active
- 2014-06-27 TN TN2015000569A patent/TN2015000569A1/en unknown
- 2014-06-27 MA MA38724A patent/MA38724B1/fr unknown
- 2014-06-27 ME MEP-2017-150A patent/ME02818B/fr unknown
- 2014-06-27 SI SI201430290T patent/SI3013318T1/sl unknown
- 2014-06-27 EP EP17160312.9A patent/EP3246017B1/fr active Active
- 2014-06-27 SG SG11201510647TA patent/SG11201510647TA/en unknown
- 2014-06-27 ES ES14742093.9T patent/ES2633989T3/es active Active
- 2014-06-27 CA CA2916222A patent/CA2916222C/fr active Active
- 2014-06-29 JO JOP/2014/0204A patent/JO3817B1/ar active
- 2014-06-30 AR ARP140102450A patent/AR096773A1/es not_active Application Discontinuation
- 2014-06-30 UY UY0001035636A patent/UY35636A/es not_active Application Discontinuation
-
2015
- 2015-12-17 PH PH12015502816A patent/PH12015502816B1/en unknown
- 2015-12-17 IL IL243210A patent/IL243210B/en active IP Right Grant
- 2015-12-28 CL CL2015003738A patent/CL2015003738A1/es unknown
-
2016
- 2016-01-12 ZA ZA2016/00238A patent/ZA201600238B/en unknown
-
2017
- 2017-07-19 CY CY171100771T patent/CY1120811T1/el unknown
- 2017-11-02 US US15/802,390 patent/US10344765B2/en active Active
-
2019
- 2019-06-03 US US16/430,322 patent/US11162500B2/en active Active
-
2021
- 2021-08-11 US US17/400,044 patent/US11959486B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38724B1 (fr) | Formulation liquide stable d'amg 416 (velcalcétide) | |
| EA201891344A1 (ru) | Новые агонисты рецептора апелина и способы применения | |
| CL2015002098A1 (es) | “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct | |
| CL2015002123A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| AR094403A1 (es) | Terapia de combinación de anticuerpos anti-her3 | |
| CL2015003290A1 (es) | Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4). | |
| EA201690667A1 (ru) | Композиции, содержащие антитело к pdl1 | |
| CL2012001853A1 (es) | Formulación farmacéutica que comprende un anticuerpo humano que se une de modo especifico al receptor de interleuquina 6 humana (hil-6r), histidina y un carbohidrato. | |
| CL2015002125A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| EA201891336A1 (ru) | Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| EP2903971A4 (fr) | Analogues de n-(3-(pyrimidin-4-yl)phényl) substitué utilisés en tant qu'inhibiteurs de récepteur tyrosine kinase btk | |
| EP2903972A4 (fr) | Analogues de n-(3-(pyrimidin-4-yl)phényl) substitué utilisés en tant qu'inhibiteurs de récepteur tyrosine kinase btk | |
| MX2018013234A (es) | Sintesis de indazoles. | |
| MX387228B (es) | Compuestos de pirazol como moduladores del receptor de hormona estimuladora de foliculo y sus usos. | |
| UY34730A (es) | Formulaciones farmacéuticas que comprenden antagonistas de ccr3 | |
| EA201591196A1 (ru) | Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств | |
| SA516370737B1 (ar) | Cgrp صيغ لمضادات مستقبل | |
| BR112018072020A2 (pt) | semaglutida em condições cardiovasculares | |
| EA201501123A1 (ru) | Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы | |
| BR112016027133A8 (pt) | derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso | |
| MX385940B (es) | Nuevos antiestrógenos heterocíclicos. | |
| AR098556A1 (es) | Aparato para procesar información, aparato de difusión y método de recepción | |
| PH12016500044A1 (en) | Vasopressin-2 receptor agonists | |
| MX2017000519A (es) | Derivados de azaspiro(4.5)decano sustituido. |